Podcasts about general medicine and primary care

Host: Shelina Ramnarine, PhD Guest: Yolanda N. Evans, MD, FAAP Recognizing how inequities can significantly impact pediatric care outcomes is essential to improving access, trust, and long-term health. Dr. Shelina Ramnarine is joined by Dr. Yolanda Evans to discuss actionable strategies that can help us deliver more inclusive care, from social determinant screeners to equity-focused frameworks. Dr. Evans is a board-certified pediatrician and adolescent medicine specialist practicing in Seattle, Washington, and she spoke about this topic at the 2025 American Academy of Pediatrics National Conference and Exhibition.

Guest: Jennifer M. Kalish, MD, PhD, FAAP Early genetic evaluation plays a vital role in identifying potential causes of neurodevelopmental disorders and guiding families on next steps, expectations, and recurrence risks. Dr. Jennifer Kalish joins us to share practical insights for recognizing when to initiate testing, selecting the right tests, and addressing barriers such as insurance and interpretation. Dr. Kalish is an Assistant Professor of Pediatrics at the University of Pennsylvania Perelman School of Medicine and the Director of the Beckwith-Wiedemann Syndrome Program at the Children's Hospital of Philadelphia. She also spoke about this topic at the 2025 American Academy of Pediatrics (AAP) National Conference and Exhibition.

Moderator: Amit Bobby Mahajan, MD, FCCP, DAABIP Guest: Jonathan Kurman, MD Guest: Surya Bhatt, MD New strategies like advanced pharmacologic agents and bronchoscopic lung volume reduction are redefining COPD and emphysema management. Dr. Bobby Mahajan sits down with Drs. Surya Bhatt and Jonathan Kurman to highlight emerging strategies for identifying ideal candidates, optimizing patient selection, and combining therapies to reduce dyspnea and improve outcomes. Dr. Mahajan is the Medical Director of Interventional Pulmonology and Complex Airway Disease Programs at the Inova Health System in Virginia, Dr. Bhatt is the Director of the Center for Lung Analytics and Imaging Research as well as the Medical Director of the Pulmonary Function and Exercise Physiology Lab and the Pulmonary Rehabilitation Program at the University of Alabama at Birmingham, and Dr. Kurman is an Associate Professor of Medicine at the Medical College of Wisconsin and the Director of Interventional Pulmonology at Froedtert and Medical College of Wisconsin Health Network. This program is produced in partnership with the American College of Chest Physicians and is sponsored by Pulmonx, the maker of the Zephyr Valve.

Guest: Michael Levy, MD, PhD Antibody-mediated demyelinating diseases, such as neuromyelitis optica spectrum disorder and MOG antibody disease, differ fundamentally from multiple sclerosis (MS) due to their association with specific antibodies. Dr. Michael Levy explains how these conditions progress, how relapses can drive disability, and why prevention is critical for improving long-term outcomes. Dr. Levy is an Associate Professor at Harvard Medical School working in the Department of Neurology at Brigham and Women's Hospital, and he spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.

Guest: Le Hua, MD Diagnosing multiple sclerosis (MS) in older patients presents unique challenges, especially as age-related comorbidities and common neurological findings often mimic MS. Hear from Dr. Le Hua as she highlights the importance of thorough clinical history, cautious interpretation of imaging, and the role of paraclinical studies in ensuring accurate MS diagnosis, particularly in patients over 50. Dr. Hua is the Director of Clinical Operations and Director of the Multiple Sclerosis Program at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. She also spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.

Guest: Le Hua, MD Diagnosing multiple sclerosis (MS) in older patients presents unique challenges, especially as age-related comorbidities and common neurological findings often mimic MS. Hear from Dr. Le Hua as she highlights the importance of thorough clinical history, cautious interpretation of imaging, and the role of paraclinical studies in ensuring accurate MS diagnosis, particularly in patients over 50. Dr. Hua is the Director of Clinical Operations and Director of the Multiple Sclerosis Program at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. She also spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.

Guest: Michael Levy, MD, PhD Antibody-mediated demyelinating diseases, such as neuromyelitis optica spectrum disorder and MOG antibody disease, differ fundamentally from multiple sclerosis (MS) due to their association with specific antibodies. Dr. Michael Levy explains how these conditions progress, how relapses can drive disability, and why prevention is critical for improving long-term outcomes. Dr. Levy is an Associate Professor at Harvard Medical School working in the Department of Neurology at Brigham and Women's Hospital, and he spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.

Guest: Laura B. Enyedi, MD Pediatricians are often the first to encounter eye conditions that can range from common to life-threatening. Hear from Dr. Laura Enyedi as she shares highlights from her presentation on diagnosing childhood ocular disorders from the 2025 American Academy of Pediatrics (AAP) National Conference and Exhibition. Dr. Enyedi is a Professor of Ophthalmology and an Associate Professor in Pediatrics at Duke University School of Medicine in Durham, North Carolina.

Host: Ryan Quigley Neonatal food protein-induced enterocolitis syndrome (N-FPIES) is an underrecognized condition often misdiagnosed as necrotizing enterocolitis, despite distinct clinical and lab features that demand a different treatment approach. In this AudioAbstract, ReachMD's Ryan Quigley explores the early signs, immune pathways, and diagnostic markers of N-FPIES, offering essential insights to help pediatric clinicians identify this condition and initiate appropriate dietary management to avoid unnecessary interventions.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: David Levinthal, MD, PhD Cyclic vomiting syndrome (CVS) is often underdiagnosed in adults due to its episodic nature and symptom overlap with other conditions. Dr. David Levinthal joins Dr. Peter Buch to explore key diagnostic criteria, key differences between CVS and cannabinoid hyperemesis syndrome (CHS), and evidence-based treatment strategies. Dr. Levinthal is the Director of the UPMC Neurogastroenterology and Motility Center and an Associate Professor of Medicine at the University of Pittsburgh School of Medicine.

Moderator: Gerard A. Silvestri MD, MS, Master FCCP Guest: Jessica S. Donington, MD, MSCR Guest: Mariam Alexander, MD, PhD Guest: Anurag Singh, MD Recent data from ASCO and ASTRO 2025 are redefining standards of care for resectable non-small cell lung cancer (NSCLC). Drs. Gerard Silvestri, Mariam Alexander, Anurag Singh, and Jessica Donington review these updates on the importance of molecular testing, careful surgical selection, and multidisciplinary planning to optimize personalized treatment pathways. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina; Dr. Alexander is an Assistant Professor of Medical Oncology at the Medical University of South Carolina; Dr. Singh is the Director of Radiation Research, Director of Head and Neck and Lymphoma Radiation Services, and the Associate Dean of Graduate Medical Education in Radiation Medicine at Roswell Park Comprehensive Cancer Center in Buffalo, New York; and Dr. Donington is a Professor of Surgery and Chief of the Section of Thoracic Surgery at the University of Chicago. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Moderator: Gerard A. Silvestri MD, MS, Master FCCP Guest: Jessica S. Donington, MD, MSCR Guest: Mariam Alexander, MD, PhD Guest: Anurag Singh, MD Effective care for non-small cell lung cancer (NSCLC) now depends on early molecular testing and coordinated input from a variety of specialties. Dr. Gerard Silvestri sits down with Drs. Jessica Donington, Mariam Alexander, and Anurag Singh to review why multidisciplinary integration is critical to avoid treatment delays, ensure appropriate therapy selection, and ultimately improve patient outcomes. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina; Dr. Donington is a Professor of Surgery and Chief of the Section of Thoracic Surgery at the University of Chicago; Dr. Alexander is an Assistant Professor of Medicine and Medical Oncology at the Medical University of South Carolina; and Dr. Singh is the Director of Radiation Research, Director of the Head and Neck and Lymphoma Radiation Services, and the Associate Dean of Graduate Medical Education in Radiation Medicine at Roswell Park Comprehensive Cancer Center in Buffalo, New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Host: Michael Ghobrial, MD Guest: Anju T Peters, MD, MSCI, FAAAAI Guest: Michael S. Blaiss, MD, FACAAI, FAAAAI Refractory chronic cough (RCC) is a debilitating condition that is often misunderstood and underdiagnosed, leaving patients with persistent symptoms despite standard treatment. Hear from Drs. Michael Ghobrial, Anju Peters, and Michael Blaiss as they clarify the definition of RCC, outline essential diagnostic steps, and review current and emerging management strategies. Dr. Ghobrial is the Director of the Chronic Cough Clinic at Cleveland Clinic; Dr. Peters is a Professor of Medicine and Associate Chief of Clinical Research and Practice and Operation in the Division of Allergy and Immunology at Northwestern Medicine; and Dr. Blaiss is a Clinical Professor of Pediatrics at the Medical College of Georgia and an allergist at Good Samaritan Health Center of Gwinnett. This episode is a non-promotional, non-CME educational program brought to you by CHEST in collaboration with GSK.

Host: Michael Ghobrial, MD Guest: Anju T Peters, MD, MSCI, FAAAAI Guest: Michael S. Blaiss, MD, FACAAI, FAAAAI Refractory chronic cough can persist for years despite guideline-based therapy, significantly affecting patients' physical, social, and psychological wellbeing. Leading experts Drs. Michael Ghobrial, Anju Peters, and Michael Blaiss explain how to distinguish RCC from other types of chronic cough, outline effective diagnostic strategies, and explore emerging treatment options. Dr. Ghobrial is the Director of the Chronic Cough Clinic at Cleveland Clinic; Dr. Peters is a Professor of Medicine and the Associate Chief of Clinical Research and Practice Innovation in the Division of Allergy and Immunology at Northwestern Medicine; and Dr. Blaiss is a Clinical Professor of Pediatrics at the Medical College of Georgia and an allergist at Good Samaritan Health Center of Gwinnett. This episode is a non-promotional, non-CME educational program brought to you by CHEST in collaboration with GSK.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Paul Kwo, MD While sometimes overlooked, minimally elevated liver tests may signal early liver disease or non-hepatic conditions like thyroid dysfunction. As a result, interpreting ALT and AST thresholds, assessing metabolic risk, and reviewing lifestyle factors can help shape a focused diagnostic approach and reduce liver-related complications. Joining Dr. Peter Buch to provide insights into the evaluation of minimally elevated liver tests is Dr. Paul Kwo, who's a Professor of Medicine and Director of Hepatology at Stanford University.

Moderator: Susan Corbridge, PhD, APRN, ACNP-BC, FAANP, FCCP, FAAN Guest: Bradford Bemiss, MD MSCR Guest: Debasree Banerjee, MD, MS, FCCP Effectively supporting patients with interstitial lung disease (ILD) requires more than just clinical knowledge—it demands strong, trust-based communication from the very first moments spent with a patient. Dr. Susan Corbridge sits down with Drs. Brad Bemiss and Debasree Banerjee to explore how the American College of Chest Physicians (CHEST)'s First 5 Minutes framework can help validate patient concerns, reduce fear, and establish a collaborative care plan from the beginning. Dr. Corbridge is a Professor Emerita at the University of Illinois Chicago College of Nursing; Dr. Bemiss is an Associate Professor of Pulmonary and Critical Care in the Department of Medicine and the Director of the Interstitial Lung Disease Program at Northwestern University; and Dr. Banerjee is an Associate Professor of Medicine in the Division of Pulmonary, Critical Care, and Sleep Medicine and an Associate Medical Director of the MICU at Brown University. This episode is a non-promotional, non-CME educational program brought to you by CHEST in collaboration with Boehringer Ingelheim.

Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.

Host: Ryan Quigley The World Health Organization's new Integrated Lung Health Resolution is the first to explicitly include lung cancer within a global lung health framework. In this AudioAbstract, ReachMD's Ryan Quigley explains what this means for screening, early diagnosis, care pathways, and equitable access to treatment.

Guest: Francis Farraye, MD Host: Peter Buch, MD, FACG, AGAF, FACP A 2025 update to the American College of Gastroenterology (ACG)'s guideline on preventive care in inflammatory bowel disease (IBD) includes key changes impacting vaccine recommendations, dermatologic screening, and care coordination. Dr. Peter Buch sits down with Dr. Francis Farraye, lead author of this guideline, to highlight what clinicians need to know. Dr. Farraye is a Professor of Medicine and the Director of the Inflammatory Bowel Disease Center at the Mayo Clinic in Jacksonville, Florida

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Iris Wang, M.D. From symptom trackers to multidisciplinary app-based platforms, evidence-based digital therapeutics are expanding access to brain-gut behavioral care for patients with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Dr. Peter Buch sits down with Dr. Iris Wang to discuss the spectrum of available tools and explore strategies for aligning them with individual patient needs. Dr. Wang is an Associate Professor of Medicine and the Associate Program Director of the Gastroenterology Fellowship at the Mayo Clinic in Rochester, Minnesota.

Host: Brian P. McDonough, MD, FAAFP Guest: Mylynda Massart, MD, PhD Given its ability to identify universal cancer signals across multiple tumor types, multi-cancer early detection (MCED) testing is emerging as a promising tool to complement traditional, single-cancer screening methods. Joining Dr. Brian McDonough to share practical strategies for introducing MCED testing into clinical workflows and enhancing patient engagement is Dr. Mylynda Massart. Not only is she an Associate Professor at the University of Pittsburgh School of Medicine, but she's also the Founder and Medical Director of the Primary Care Precision Medicine Clinic and Associate Director of Clinical Services for the Institute for Precision Medicine at the University of Pittsburgh Medical Center.

Host: Brian P. McDonough, MD, FAAFP Guest: Marie Wood, MD Traditional cancer screening has always focused on individual organs, but now, multi-cancer early detection (MCED) tests are changing that paradigm. By analyzing multiple biomarkers through a single blood draw, MCED testing can detect signals from a variety of cancers—many of which currently lack effective screening tools. These multi-biomarker approaches not only outperform single-marker tests, but also demonstrate scientific rigor and clinical utility. Still, challenges remain, including false positives and integration with standard screening protocols. Joining Dr. Brian McDonough to explore the rationale for using a multi-biomarker approach to MCED testing is Dr. Marie Wood, Professor of Medicine at the University of Colorado School of Medicine and Medical Director of the Hereditary Cancer Program at the CU Cancer Center.

Host: Ryan Quigley Guest: Hallie Blevins, PhD. Guest: Marlene Mimi Maeusli, PhD. With one in three eligible Americans still unscreened for colorectal cancer (CRC), there's an urgent need for noninvasive and affordable alternatives to colonoscopy. A 2025 study published in ACS Sensors introduces a novel aptamer-based colorimetric assay that targets Parvimonas micra—a gut microbe linked to CRC. To learn more, Mr. Ryan Quigley speaks with Drs. Hallie Blevins and Mimi Maeusli about how this technology works, what sets it apart from current testing methods, and why it could play a role in improving early CRC detection. Reference: Feng S, Zhang P, Chen H, et al. Au@Fe3O4 nanoparticle-based colorimetric aptasensor for noninvasive screening of colorectal cancer via detection of Parvimonas micra. ACS Sens. 2025;10(2):1053-1062.

Host: Jennifer Caudle, DO Guest: Blen Girmay, MD Because standard-dose vaccines usually produce only modest immunogenic responses in people age 65 years and older, the Advisory Committee on Immunization Practices, as of June 2022, recommended this age group receive either an adjuvanted or higher-dose seasonal influenza vaccine.1,2,3 A pragmatic, head-to-head randomized study compared FLUAD and the high-dose influenza vaccine over the course of two influenza seasons.2 Joining Dr. Jennifer Caudle to discuss this study and its findings from the first season (2023-2024) is Dr. Blen Girmay, a Johns Hopkins fellowship-trained primary care geriatrician at Inova Health System in Fairfax, Virginia. References: Coleman BL, Sanderson R, Haag MDM, McGovern I. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respir Viruses. 2021;15(6):813-823. Klein N. Oral presentation presented at: IDWeek 2024 Meeting; October 16-19, 2024. Los Angeles, CA. Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season. MMWR Recomm Rep. 2024;73(5):1-25.

Immune imprinting refers to how the immune system's first encounter with a virus, such as influenza, leaves a lasting imprint that shapes future immune responses.1,2 However, influenza vaccines may affect this process—particularly when egg-based ones are used. Tune in to learn about the impact of immune imprinting, the role that vaccines play in this process, and how switching to non-egg-based vaccines could help redirect immune responses and possibly create more effective defenses in people of all ages.3,4 References: King SM, Bryan SP, Hilchey SP, Wang J, Zand MS. First impressions matter: Immune imprinting and antibody cross-reactivity in influenza and SARS-CoV-2. Pathogens. 2023;12(2):169. doi:10.3390/pathogens12020169 Zhang A, Stacey HD, Mullarkey CE, Miller MS. Original antigenic sin: How first exposure shapes lifelong anti-influenza virus immune responses. J Immunol. 2019;202(2):335–340. doi:10.4049/jimmunol.1801149 Rockman S, Laurie K, Ong C, et al. Cell-based manufacturing technology increases antigenic match of influenza vaccine and results in improved effectiveness. Vaccines (Basel). 2022;11(1):52. doi:10.3390/vaccines11010052 Liu F, Gross FL, Jefferson SN, et al. Age-specific effects of vaccine egg adaptation and immune priming on A(H3N2) antibody responses following influenza vaccination. J Clin Invest. 2021;131(8):e146138. doi:10.1172/JCI146138 USA-CRP-24-0038 July 2025

Host: Jennifer Caudle, DO Guest: Johanna Finkle, MD, FACOG As GLP-1 therapies grow in popularity for weight management and diabetes, an unexpected consequence has emerged: a rise in unplanned pregnancies due to reduced oral contraceptive effectiveness. Dr. Jennifer Caudle sits down with Dr. Johanna Finkle, a weight loss specialist and OB/GYN at the University of Kansas Health System, to explore the mechanisms behind this trend and outline practical, long-acting contraceptive alternatives that maintain efficacy during GLP-1 use.

CME credits: 1.00 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/identifying-a-key-cause-of-hard-to-control-diabetes/36543/ The diagnosis of hypercortisolism is often delayed or missed, especially in primary care settings, leading to detrimental consequences for patients, such as unnecessary morbidity and mortality. Recent data suggest that the prevalence of hypercortisolism is far higher than previously estimated. Clinicians need to be aware of optimal approaches for identifying, diagnosing, and treating hypercortisolism. New data are emerging for hypercortisolism treatments that can improve outcomes in patients with hypercortisolism and hard-to-control type 2 diabetes. =

CME credits: 1.00 Valid until: 08-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/stemming-the-tide-on-masldmash-it-starts-on-the-frontlines-in-endocrinology-and-primary-care-clinics/35568/ The epidemic of metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) is fully upon the US healthcare system, and it's projected to get worse. The prevalence of MASLD in the US is expected to increase from 33.7% in 2020 to 41.4% in 2050, which translates to approximately 122 million adults being affected. Our broadcast on Global Fatty Liver Day provides practical and engaging discussions to help endocrinologists and primary care providers better understand the use of noninvasive tests and biomarkers for timely screening and primary risk assessment, treatment and management of cardiometabolic risk, and assignment to the appropriate level of care for patients with MASLD/MASH. =

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Michael Camilleri, MD GLP-1 receptor agonists are revolutionizing treatment for diabetes and obesity, but their impact on the gastrointestinal tract demands careful clinical attention. Dr. Peter Buch is joined by Dr. Michael Camilleri, Professor of Medicine at the Mayo Foundation for Medical Education and Research in Rochester, Minnesota, to discuss key findings on gastrointestinal side effects, procedural risks, and the impacts of GLP-1 receptor agonists on the fields of gastroenterology and hepatology.

CME credits: 1.00 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/where-does-this-patient-land-making-sense-of-risk-and-ldl-c-goals/35815/ Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

CME credits: 1.00 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-dose-matters-optimizing-statin-intensity-in-ascvd-management/35816/ Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

CME credits: 1.00 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/expanding-access-alternative-models-for-delivering-lipid-lowering-therapy/35817/ Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

CME credits: 1.00 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/when-and-why-to-use-cac-scoring/35818/ Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

CME credits: 1.00 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/statins-and-safety-what-the-data-say-about-dementia-cancer-and-more/35819/ Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

CME credits: 1.00 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/closing-the-loop-practical-strategies-for-timely-lipid-panel-follow-up/35820/ Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

CME credits: 1.00 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/target-in-sight-escalating-therapy-to-reach-ldl-c-goals/35821/ Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

CME credits: 1.00 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-ldl-c-treatmentnovel-options-that-align-with-patient-preferences/35822/ Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

CME credits: 1.00 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/unmasking-hidden-risk-the-role-of-lpa-in-cardiovascular-risk-assessment/35823/ Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

CME credits: 1.00 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/bridging-ascvd-care-between-academic-and-rural-settings/35824/ Join our experts for case-based episodes that focus on bridging the gap between rural health and cardiovascular disease. Experts will explore ASCVD prevention and treatment by reviewing patient risk factors and determining ASCVD risk reduction strategies. This activity is designed to empower healthcare professionals with the knowledge and tools needed to make impactful decisions in cardiovascular care.

CME credits: 0.25 Valid until: 10-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/innovative-approaches-to-managing-ckm-syndrome-and-hfmrefhfpef/29912/ Listen to Dr. Riccardo Inciardi's summary from the ESC Preventive Cardiology 2025 meeting, where he highlights new therapies reshaping the management of cardio-kidney-metabolic (CKM) syndrome and heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Watch as he breaks down the latest clinical trial data showing that SGLT2 inhibitors, GLP-1 receptor agonists, and the nonsteroidal MRA finerenone can meaningfully reduce hospitalizations, kidney disease progression, and cardiovascular mortality. A real-life patient case illustrates how combining these therapies—under the care of a multidisciplinary team—can transform outcomes.=

CME credits: 0.25 Valid until: 06-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/nonsteroidal-mra-sglt2i-in-people-with-ckd-t2d-current-evidence-and-rationale-for-combination-therapy/29909/ Can combining a nonsteroidal MRA and an SGLT2 inhibitor unlock new clinical potential for patients with type 2 diabetes and chronic kidney disease (CKD)? In this expert discussion, Dr. Jennifer Green and Dr. Hiddo Heerspink review the latest findings from the CONFIDENCE trial, which demonstrated a significant additive reduction in albuminuria—an important surrogate marker for kidney and cardiovascular risk—when finerenone and empagliflozin are used together. They explore the clinical rationale behind combination therapy, address persistent challenges in CKD detection, and consider the practical implications for implementing these therapies in high-risk populations.=

CME credits: 0.50 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/obesity-and-comorbidities-strategies-for-effective-patient-management/35827/ This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care. This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

CME credits: 0.50 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/practical-tips-for-glp-1-ra-therapy-success/35830/ This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care. This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

CME credits: 0.50 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/beyond-the-scale-how-to-tackle-obesitys-comorbidities/35829/ This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care. This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

CME credits: 0.50 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/treating-obesity-lifelong-strategies-from-lifestyle-to-pharmacotherapy-and-surgery-treating-obesity-lifelong-strategies-ffrom-lifestyle-to-pharmacotherapy-and-surgery/35828/ This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care. This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

CME credits: 0.50 Valid until: 30-05-2026 Claim your CME credit at https://reachmd.com/programs/cme/obesity-unmasking-the-chronic-disease-beneath-the-weight/35826/ This 5-part series redefines obesity as a chronic, biologically driven disease. It addresses the impact of stigma, the management of common comorbidities, and the full spectrum of treatment options—from lifestyle interventions to GLP-1 receptor agonists and bariatric surgery. Practical guidance, patient cases, and expert insights help primary care providers deliver respectful, effective, and sustainable obesity care. This program has been put together in collaboration with Sarah le Brocq - Founder of organization All About Obesity CIC – www.allaboutobesity.org

CME credits: 1.25 Valid until: 30-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/integrating-new-therapies-into-healthcare/35553/ Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.

CME credits: 1.25 Valid until: 30-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/considering-the-promise-of-new-and-emerging-treatments-for-hemophilia-managing-thrombotic-risks/35552/ Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.

CME credits: 1.25 Valid until: 30-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/evaluating-emerging-treatment-options-rebalancing-therapies/35549/ Stay ahead in hemophilia care with the new and emerging therapies transforming treatment approaches. The entire care team should be prepared to apply these innovations in a personalized way. This activity delivers key insights from the recent HTRS meeting along with foundational knowledge on novel therapies, presented in 5-minute modules for easy learning. *This content has not been endorsed by HTRS.